Market Overview

Enanta Pharmaceuticals to Present New Data on its RSV Inhibitor EDP-938 at the 11th International Respiratory Syncytial Virus Symposium

Share:

Final Data from Enanta's Phase 1 study in healthy volunteers will
be presented on November 1
st

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that two abstracts have been accepted for presentation at the 11th
International Respiratory Syncytial Virus Symposium in Asheville, North
Carolina, October 31 through November 4, 2018.

New data will be presented from the following two abstracts:

  • "EDP-938, a Novel, Non-Fusion Replication Inhibitor of Respiratory
    Syncytial Virus: Preliminary Results of a Phase 1 Study in Healthy
    Subjects (HS)"
  • "EDP-938, a Novel Non-Fusion Replication Inhibitor of RSV, Displays
    a High Barrier to Resistance In Vitro"

About EDP-938
EDP-938, Enanta's lead non-fusion inhibitor,
is being developed for the treatment of RSV infection. Enanta believes a
non-fusion approach differentiates its compounds from fusion inhibitors
currently in development for RSV because non-fusion inhibitors target
the virus replication machinery and have demonstrated high barriers to
resistance against the virus in vitro. EDP-938 has also been
shown to reduce viral load below the level of detection in vivo.
Additionally, non-fusion inhibitors have the potential of being
effective at later stages of infection.

About RSV
Respiratory syncytial virus (RSV) is a virus that
infects the lungs and represents a serious unmet medical need in infants
and children, as well as immune-compromised individuals and the elderly.
RSV is the most common cause of bronchiolitis (inflammation of the small
airways in the lung) and pneumonia in children under 1 year of age in
the United States. Each year, 57,000 to 125,000 children in this group
are hospitalized due to RSV infection. Children with compromised
(weakened) immune systems due to a medical condition or medical
treatment, adults with compromised immune systems and those 65 and older
are also at increased risk of severe disease. There is currently no
effective treatment available for treating RSV infection.

About Enanta
Enanta Pharmaceuticals is using its robust,
chemistry-driven approach and drug discovery capabilities to become a
leader in the discovery and development of small molecule drugs for the
treatment of viral infections and liver diseases. Two protease
inhibitors, glecaprevir and paritaprevir, discovered and developed
through Enanta's collaboration with AbbVie, have now been approved
around the world as part of AbbVie's regimens for the treatment of
hepatitis C virus (HCV) infection. The leading regimen is sold under the
tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.)
(glecaprevir/pibrentasvir).

Royalties from the AbbVie collaboration are helping to fund Enanta's
research and development efforts, which are currently focused on the
following disease targets: non-alcoholic steatohepatitis (NASH), primary
biliary cholangitis (PBC), respiratory syncytial virus (RSV) and
hepatitis B virus (HBV). Please visit www.enanta.com
for more information.

View Comments and Join the Discussion!